Pharmatek, a contract development and manufacturing organization supporting the pharmaceutical industry, today announced that it has made a substantial investment into its spray drying capabilities. The Company has purchased a second GEA Niro Mobile Minor™, in addition to a ProCepT™ 4M8-Trix™, and a GEA Niro SD Micro™ for the development and GMP manufacture of amorphous spray dried dispersions (SDD).
The purchases complement existing spray drying equipment, including a GEA Niro Mobile Minor and a Buchi B-290. Pharmatek has seen rising demand in SDD across the industry and received specific client requests to increase spray dry capacity.
“Expanding our SDD capacity is driven by significant client demand and is part of Pharmatek’s continuing efforts to provide a comprehensive range of bioavailability enhancement solutions for our clients,” said Tim Scott, president of Pharmatek. “We are committed to adding new technologies and increasing capacity in development areas that our clients care about.”
Pharmatek offers formulation development, process scale-up and GMP manufacturing services for small molecules and peptides. Spray drying is part of the Company’s comprehensive amorphous dispersion drug development capabilities that include physical characterization, preformulation testing, analytical development, formulation development and GMP manufacturing of finished dosage forms.
Spray drying is a key component of the Company’s solubility enhancement toolkit and platform screening program. The Company’s robust suite of technologies includes micronization, spray drying, hot-melt complexation, and liquid-filled-capsule development. Utilizing a data-driven, agnostic approach, Pharmatek screens multiple technologies to determine the best path forward for a given compound and client.Leave a reply →